NSRX

Nasus Pharma Ltd. (NSRX) Economic Moat Analysis (2026)

Invetso Score: 1.7/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Intangible Assets

Score: 2.4 (Weak)

NSRX shows no provided evidence of durable brand, patent, regulatory, or data advantages, so it lacks the kind of protected intangible assets that typically sustain pricing power versus peers.

The negative TTM ROIC and ROCE suggest any existing intangibles are not translating into economic returns, which is weaker than peers with proven monetizable IP or franchise strength.

No 5-year margin or growth history was provided, so there is no support for persistent intangible-driven retention or premium pricing relative to competitors.

Switching Costs

Score:

The provided metrics do not indicate customer lock-in, workflow dependence, or contractual stickiness, so switching costs appear minimal versus peers.

A cash conversion cycle of 0 and asset turnover of 0 do not evidence embedded customer relationships or recurring usage that would make replacement costly.

Negative ROIC and ROCE imply the business is not capturing retention economics better than peers, which is inconsistent with meaningful switching costs.

Network Effects

Score:

No evidence was provided of user-to-user, data, or ecosystem feedback loops, so network effects are not visible versus peers.

The absence of positive profitability and efficiency signals makes it unlikely that scale is compounding into a stronger platform effect than competitors.

Without disclosed adoption, engagement, or ecosystem metrics, there is no basis to infer a self-reinforcing network advantage.

Cost Advantage

Score:

Negative ROIC and ROCE indicate NSRX is not demonstrating a cost structure that converts into superior returns versus peers.

The provided efficiency metrics do not show asset productivity or working-capital advantages that would support a durable unit-cost edge.

With no margin history or scale evidence, there is no support for a persistent cost advantage over competitors.

Efficient Scale

Score:

The available data do not show a niche market structure or capacity constraints that would allow NSRX to earn excess returns from efficient scale versus peers.

Negative returns on capital argue against a protected position where limited market size deters entry and preserves economics.

No evidence was provided that the company operates in a concentrated market with stable share and rational competition, so efficient-scale benefits appear absent.

Overall Score

Score:

NSRX appears to have a weak and non-durable moat versus peers because the provided metrics show negative capital returns and no evidence of protected intangibles, switching costs, network effects, cost advantage, or efficient-scale benefits.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Nasus Pharma Ltd.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →